Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc receives FDA approval for ISENTRESS


Wednesday, 8 Jan 2014 08:30am EST 

Merck & Co Inc:Says the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor.With this approval, ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older.